Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023

Mickaël Hiligsmann,Mitchell P. DeKoven,Riddhi Doshi,Carolyn Gotay,Carlo Lazzaro,Jayashri Sankaranarayanan,Rayya Hajjar
DOI: https://doi.org/10.1080/14737167.2024.2339945
2024-04-11
Expert Review of Pharmacoeconomics & Outcomes Research
Abstract:KEYWORDS: Expert Review of Pharmacoeconomics & Outcomes Research (ERP) is a prestigious journal within the field of health economics and outcomes research, distinguished for its commitment to publishing high-quality, pertinent, and diverse content. The journal's burgeoning impact within its field and output owes much to the contributions of our esteemed authors, who consistently submit relevant and exemplary research to ERP, as well as our dedicated editorial board, who provide invaluable guidance, and our peer reviewers, who offer exceptional support in enhancing the quality, rigor, and presentation of submitted papers.
pharmacology & pharmacy,health care sciences & services,health policy & services
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to summarize and evaluate high - impact articles published in the journal "Expert Review of Pharmacoeconomics & Outcomes Research" in 2023. By inviting members of the editorial board to nominate the articles they consider most important and provide brief comments to expound on the importance of these articles, the paper aims to highlight the contributions of these studies to the fields of pharmacoeconomics and outcomes research. Specifically, the paper covers the following aspects: 1. **Economic evaluation recommendations**: The article "Recommendations for economic evaluation of cell and gene therapies: A systematic literature review and critical appraisal" [1] selected by Mickaël Hiligsmann aims to address the multi - faceted challenges in the clinical, economic, and reimbursement fields after gene therapies enter the market. The article proposes 21 key recommendations for guiding the economic evaluation of gene therapies and points out that most current studies fail to follow these standards, emphasizing the importance of future studies needing to adhere more closely to these standards. 2. **Value measurement methods**: Mitchell P. DeKoven selected "Value measurement of innovative approaches in the US Medicare drug price negotiation program: An update" [2], which explores six potential methods for evaluating drug value without using quality - adjusted life years (QALYs). The article evaluates the cost - effectiveness and comparative effectiveness of these methods, as well as their abilities in reducing discrimination, feasibility, transparency, flexibility, etc. 3. **Economic value of BRCA gene testing**: Carolyn Gotay selected three articles on the economic value of BRCA gene testing in breast cancer prevention, optimization of treatment for recurrent epithelial ovarian cancer, and prostate cancer prevention and optimal treatment [3][4][5]. These studies analyzed the impact of knowing the BRCA mutation status on short - and long - term outcomes, including cancer incidence, treatment options, morbidity, and mortality, etc., through modeling, and evaluated the costs from the perspectives of payers and society. The research results show that knowing the BRCA mutation status is cost - saving for both payers and society. 4. **Economic model evidence for rare disease treatment**: The article "Review of economic model evidence for the treatment of spinal muscular atrophy by NICE" [6] selected by Carlo Lazzaro focuses on the assessment of the treatment of spinal muscular atrophy by the National Institute for Health and Care Excellence (NICE) in the United Kingdom, especially the situation where NICE's willingness to pay for the treatment of rare diseases is higher than the normal range, and the impact of considering the decline in the utility of family members of patients on the incremental cost - effectiveness ratio (ICUR). 5. **Differences in evidence requirements for oncology drug effectiveness evaluation**: The article "Differences in evidence requirements for oncology drug effectiveness evaluation among six European health technology assessment agencies - Can consistency be improved?" [10] selected by Jayashri Sankaranarayanan studies the differences in evidence requirements for the relative effectiveness evaluation of oncology drugs among different European health technology assessment (HTA) agencies and proposes suggestions for improving consistency, such as joint early dialogue and strengthening international cooperation. Through the exploration of these issues, the paper not only provides an in - depth understanding of high - impact articles in 2023 but also offers valuable guidance for future research directions and policy - making.